Presumed aetiology of IPH and of haemorrhagic imaging markers (CMB-group)
| Etiologic considerations | IPH (62)* | CMB-group24 |
| Cerebral amyloid angiopathy (CAA) | ||
| Probable CAA | 26 (41.9%) | 10 (41.6%) |
| Possible CAA | 5 (8.1%) | 2 (8.3%) |
| Hypertensive cerebral small vessel disease (HTN-cSVD) | ||
| Pure deep ICH/CMBs | 18 (29.0%) | 3 (12.5%) |
| Mixed location ICH/CMBs, no cSS | 8 (12.9%) | 8 (33.3%) |
| Mixed location ICH/CMBs/cSS (real mixed pathology) | 2 (3.2%) | 0 |
| Others | ||
| Brain metastasis | 1 (1.6%) | |
| AVM related | 1 (1.6%) | |
| Cavernous angiomas | 1 (1.6%) | |
| Unknown distribution | 1 (4.2%) | |
*Including non-aneurysmal convexity subarachnoid haemorrhage.
.AVM, arteriovenous malformation; CMB, cerebral microbleed; cSS, cortical superficial siderosis; ICH, intracranial haemorrhage; IPH, intraparenchymal haemorrhage.